Review anchor
GABA A receptor alpha-2/beta-2/gamma-2
PROTEIN COMPLEX · Rattus norvegicus
As of 2026-09-13
Evidence Snapshot
GABA A receptor alpha-2/beta-2/gamma-2
CHEMBL2111327
PROTEIN COMPLEX
Rattus norvegicus
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats GABA A receptor alpha-2/beta-2/gamma-2 as ChEMBL target CHEMBL2111327, mapped to UniProt P18508. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2111327
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P18508
Gamma-aminobutyric acid receptor subunit gamma-2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why GABA A receptor alpha-2/beta-2/gamma-2 matters
GABA A receptor alpha-2/beta-2/gamma-2 is reviewed as Gamma-aminobutyric acid receptor subunit gamma-2 (UniProt P18508); the current evidence base includes 2 approved drugs, 52 compounds, and 18 assays, with lead potency reaching pChEMBL 7.9.
Protein context
Gamma-aminobutyric acid receptor subunit gamma-2
Gamma-aminobutyric acid receptor subunit gamma-2 Sequence length is 466 aa.
Review this target as GABA A receptor alpha-2/beta-2/gamma-2, mapped to UniProt P18508. ChEMBL maps the protein component as Gamma-aminobutyric acid receptor subunit gamma-2. Sequence length is 466 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P18508
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 52 compounds, and 18 assays for this target. The dominant activity type is KI. CHEMBL372281 is the current potency anchor at pChEMBL 7.9.
Use CHEMBL372281 as the tractability anchor when discussing potency (pChEMBL 7.9).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 7.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why GABA A receptor alpha-2/beta-2/gamma-2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P18508, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
52
Total Compounds
18
Total Assays
2
Approved Drugs
KI: 28.0, EC50: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL372281
|
7.9 | Ki | — |
|
|
No preferred name
CHEMBL192554
|
7.8 | Ki | — |
|
|
No preferred name
CHEMBL191088
|
7.8 | Ki | — |
|
|
No preferred name
CHEMBL502159
|
7.8 | Ki | — |
|
|
No preferred name
CHEMBL522061
|
7.7 | Ki | — |
Source Header